MedTrace Logo

Renal Impairment Study

NCT00863161 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.

Conditions

  • Reflux
  • Renal Excretion

Interventions

DRUG

AZD3355

capsule, oral, single dose

Sponsors & Collaborators

Principal Investigators

  • Wolfgang Kuhn, MD · Quintiles AB, Phase I Services, Strandbodgatan 1, 753 23 Uppsala, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863161 on ClinicalTrials.gov